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Expression of clusterin in human renal diseases. Clusterin, a glyco-
protein with potent cohesive properties, is induced in a wide variety of
acute and chronic experimental renal diseases. The purpose of this
study was to examine clusterin expression in human renal diseases.
Clusterin immunostaining was examined in nephrectomy specimens
from patients with autosomal-dominant polycystic kidney disease (N =
5),autosomal-recessive polycystic kidney disease (N = 3), multilocular
cyst of the kidney (N = 2), renal hypoplasia/dysplasia (N = 7), Wilms'
tumor (nephroblastoma) (N = 6), renal cell carcinoma (N = 9), and
acute and/or chronic renal transplant rejection (N = 15). No clusterin
staining was detected in normal renal tissue distant from renal cell
carcinomas. Increased expression of clusterin was found in epithelial
cells lining cysts in all of the cystic disorders studied. Clusterin
expression was found in some immature tubules in hypoplastic/dysplas-
tic kidneys and in tubules of rejected renal allografts, but was not a
prominent finding in renal neoplasms, although some renal cell carci-
nomas expressed clusterin in a focal manner. Common features of
clusterin induction included exclusively epithelial production of clus-
term in cysts, immature nephrons, and injured tubules, heterogeneity of
clusterin expression, with only some tubules and/or cysts in a given
area staining for clusterin, and uniform clusterin staining of epithelial
cells in a given tubule or cyst in most cases. Based on its cohesive
properties, we speculate clusterin functions to maintain cell-cell and
cell-substratum interactions which become perturbed in the setting of
renal injury and cystic diseases.
The injured cell mounts a number of unique responses
directed at minimizing damage and initiating repair. The study
of these injury responses has the potential to provide insight
into mechanisms of injury and potential therapies to limit injury
and accelerate repair.
Clusterin is a heterodimeric glycoprotein first isolated from
ram rete testes fluid, and so named because of its ability to elicit
clustering of Sertoli and red blood cells [1, 2]. Species and
tissue homologues of clusterin have been isolated and/or cloned
by a number of groups working in widely divergent areas
resulting in a number of different names for clusterin including
complement cytolysis inhibitor or CLI, sulfated glycoprotein-2
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or SGP-2, testosterone repressed prostate message-2 or
TRPM-2, dimeric acidic glycoprotein or DAG, SP-40,40, gp8O,
apolipoprotein J, NA1/NA2, and glycoprotein III [reviewed in
3—7]. In accordance with recent consensus regarding clusterin
terminology, this protein will be referred to as clusterin in this
manuscript [4]. The pathways leading to clusterin have included
studies of Sertoli cell biology, fertility, apoptosis, complement
regulation, renal tubular injury, lipid transport, Alzheimer's
disease, and others.
Clusterin is induced during renal and other tissue injuries
[3—7]. Despite its immediate and often prominent recruitment
after injury, the role of clustenn remains elusive. We, and other
investigators have demonstrated an increase in renal clusterin
mRNA or protein in such experimental models of acute renal
injury as ischemialreperfusion, ureter obstruction, gentamicin
nephrotoxicity, rhabdomyolysis and folic acid nephropathy
[8—13]. Persistent increased expression of clusterin occurred in
several chronic models of renal disease including renal ablation,
tubulointerstitial disease induced by dietary deficiency of vita-
min E and selenium, and in a mouse model of polycystic kidney
disease [13—15]. Studies in human renal disease have demon-
strated clusterin predominantly in glomerular immune deposits
usually in association with other complement components [16,
17]. Tubular staining for clusterin has either not been a promi-
nent feature of the diseases studied [16] or details regarding
such tubular staining have not been provided [17]. Neither of
these studies examined clusterin in cystic disorders.
Despite the marked tubular epithelial cell induction of clus-
term in experimental models of renal injury, limited details
regarding tubular expression of clusterin in human renal disease
are available; therefore, we examined the expression of clus-
term in acute and chronic renal transplant rejection, a common
human example of tubular injury. Since the phenotype of the
cells in human cystic diseases and renal cell cancers share
certain characteristics with those of injured cells, including
dedifferentiation and loss of cell-cell and cell-substratum inter-
actions, we also studied the expression of clusterin in these
disorders. Such cataloguing of clustenn was performed to
clarify and extend our understanding of clusterin in human renal
diseases, to evaluate the possible clinical relevance of clusterin,
and to provide insight and allow speculation on the role of
clusterin in kidney injury.
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Methods
Patients
Tissue for immunohistochemical studies was selected from
nephrectomy specimens obtained at the University of Minne-
sota between 1985 and 1990. A total of 47 kidneys were studied
encompassing a spectrum of renal disease with an emphasis on
renal cystic disease, cancer of the kidney, and allograft rejec-
tion. The samples were classified according to disease based on
clinical and pathologic criteria. Pathologic diagnoses were as
follows (Table 1): autosomal-dominant polycystic kidney dis-
ease (N = 5), autosomal-recessive polycystic kidney disease (N
= 3), multilocular cyst of the kidney (multilocular cystic
nephroma) (N = 2), renal hypoplasialdysplasia (N = 7), Wilms'
tumor (nephroblastoma) (N = 6), renal cell carcinoma (N = 9),
and acute and/or chronic renal transplant rejection (N = 15).
Immunohistochemistry
For detection of clusterin, a mouse anti-human monoclonal
antibody (G7, a gift from Dr. Brendan Murphy, University of
Melbourne, Melbourne, Australia) was used [181. Specificity of
the antibody was demonstrated by immunoprecipitation and
Table 1. Patient characteristics
Diagnosis Age Cr Reason for nephrectomy Clusrin staining
58
53
51
4
58
5
7 mo.
3 wk.
68
57
1.4
9.9
12.9
12.0
1.8
4.0
1.0
1.4
7.9
1.2
54
33
40
69
39
5
17
30
46
25
42
30
45
46
25
1.9
2.5
5.4
5.0
11.1
3.9
10.8
6.0
1.5
9.9
8.0
7.0
11.3
12.3
1.5
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Western blot analysis using both human serum and seminal fluid
[18, 19]. Sections from formaldehyde-fixed, paraffin embedded
tissue were deparaffinized in Americlear (American Scientific
Products, Minneapolis, Minnesota, USA). Endogenous perox-
idase was blocked with 0.8% hydrogen peroxide in absolute
methanol. The sections were stained with the avidin-biotin-
peroxidase complex technique as previously described [20].
Briefly, alter overnight incubation at 4°C with the primary
antibody (mouse anti-human clusterin monoclonal antibody)
the sections were incubated with biotinylated horse antiserum
which recognizes mouse IgG, and subsequently, with avidin-
biotin-peroxidase complex (Vector Laboratories, Inc., Burlin-
game, California, USA). The reaction was demonstrated with
3-3' diaminobenzidine tetrahydrochloride (0.25 mg/nil) (Sigma,
St. Louis, Missouri, USA) and 0.003% peroxide. The sections
were counter stained with Harris' hematoxylin. Negative con-
trols consisted of sections in which non-immune mouse ascites
was substituted for primary antisera.
Results
Controls
Non-immune ascitic fluid, which was used as a negative
control, did not result in any specific staining. No clusterin
staining was seen in normal renal tissue distant from renal cell
carcinomas (Fig. 1A).
Polycystic kidney disease
The kidneys of five patients with end-stage renal disease
secondary to autosomal-dominant polycystic kidney disease
were examined. In all five cases, clusterin staining was present
in epithelial cells lining both large and small renal cysts.
Intercyst heterogeneity was present with not all cysts in a given
kidney staining for clusterin. There were no morphologic dif-
ferences between cysts which stained for clusterin and those
which did not. Often positive and negative cystic tubules were
present in the same field (Fig. lB and C). When one cell in a
cyst expressed clusterin, all cells lining that cyst were immu-
noreactive. In addition, tubular casts and sloughed epithelial
cells demonstrated clustenn staining (Fig. 1 C, D). In some
sections (Fig. 1D) cells staining positive for clusterin were being
sloughed into the tubular lumen.
An identical pattern of clusterin staining was seen in the
kidneys from three patients with autosomal-recessive polycys-
tic kidney disease, including the focal nature of clusterin
staining with positive cysts interspersed with negative ones, the
staining of all epithelial cells in a given positive cyst and the
presence of clusterin in tubular casts. No glomerular, vascular,
or interstitial staining was seen in any of the cases of polycystic
kidney disease.
Multilocular cyst of the kidney
Similar to the findings in cases of polycystic kidney disease,
clusterin staining was seen in the epithelial cells lining some of
the cysts (Fig. 1E).
Renal dysplasia
The kidneys of seven patients with renal hypoplasia/dysplasia
were examined. Many of the tubules from these kidneys exhib-
ited cystic dilatation. The renal hypoplasia was characterized
by lack of normal nephron differentiation, with loose aggregates
of immature tubules surrounded by immature mesenchymal or
fibromuscular collarettes. In some cases, focal aggregates of
cartilage were identified. In many cases, superimposed changes
of hydronephrosis and/or pyelonephritis were evident.
Tubular epithelial clusterin was found in primitive tubules
and epithelial cells lining cysts. As was seen in the other cystic
disorders, clusterin was present in a focal manner with only
some cysts demonstrating staining. In both cysts and tubules
which stained for clusterin, all epithelial cells in a given section
of a positive tubule or cyst stained for clusterin. No glomerular,
vascular, interstitial, or stromal staining for clusterin was
detected (Fig. 1 F, G, H).
Renal cancer
Clusterin staining was examined in the kidneys of six patients
with Wilms' tumor (nephroblastoma), and in nine patients with
renal cell carcinoma. Blastematous, epithelial and stromal cells
in most cases of Wilms' tumor were negative for clusterin (Fig.
11). The only positive staining was observed in one tumor in
which the epithelial cells lining some neoplastic cysts were
immunoreactive. Clusterin positivity was present in some nor-
mal appearing tubules entrapped by the tumor (Fig. li).
Focal epithelial cell staining for clusterin was present in some
tumor cells in five patients with renal cell carcinoma (Fig. 1K).
In addition, in one tumor with cystic changes, clusterin was
seen in the epithelial cells lining the cysts.
Renal transplant rejection
Kidneys from 15 patients undergoing nephrectomy for renal
transplant rejection were studied. Five patients had severe
acute rejection, four patients had chronic rejection, and six
patients had combinations of acute and chronic rejection. No
qualitative differences were seen in clusterin staining in acute
versus chronic rejection. Clusterin was present in both normal
and injured tubular epithelial cells but not in glomeruli, vessels
or interstitium. No relationship was present between histologic
lesions of rejection and clusterin staining. As was seen in renal
dysplasia and polycystic kidney disease, clusterin positivity
occurred in a focal manner, with marked internephron hetero-
geneity, with some tubules staining positive whereas adjacent
ones were negative (Fig. 1 L—P). In addition, intranephron
heterogeneity of clusterin staining was present in some kidneys,
with both positive and negative cells being present in a given
tubule (Fig. 10). Tubular casts, at times made up of sloughed
tubular epithelial cells, also stained for clusterin (Fig. 1P). The
cast material was usually present in tubules which stained for
clusterin, although this was not always the case (Fig. 1L).
Discussion
Expression of clusterin was found in epithelial cells lining
cysts in a variety of human renal diseases, including autosomal-
dominant and autosomal-recessive polycystic kidney disease,
multilocular cyst of the kidney, cystic renal dysplasia, and in
neoplastic cysts found in some cases of Wilms' tumor and renal
cell carcinoma. In addition, clusterin expression was seen in
immature tubules in hypoplastic/dysplastic kidneys and in some
tubules of rejected renal allografts, but was not a prominent
finding in renal neoplasms, although some renal cell carcinomas
expressed clusterin in a focal manner. Several common features
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of clusterin induction were revealed by these studies and
include the exclusively tubular epithelial production of clusterin
in cysts, immature nephrons, and injured tubules. A heteroge-
neous pattern of clusterin staining was observed, with only
some tubules and/or cysts in a given area staining for clusterin.
In most cases, clustenn was present in all of the epithelial cells
in a given tubule or cyst with the exception of some tubules in
rejected kidneys where intratubular heterogeneity was seen.
Many of these features of clusterin expression in human renal
disease are similar to our observations in experimental renal
diseases [12—14].
Previous studies examining expression of clusterin in human
renal diseases have focused primarily on the relationship be-
tween clusterin and complement. Murphy et al examined clus-
term staining in 90 renal biopsies of patients with a variety of
renal diseases [16]. The major finding was co-localization of
clusterin with complement components of the membrane attack
complex (C6 and C9) and S-protein. This was particularly true
in patients with immune complex glomerulonephritis, but was
also found in glomeruli of patients with focal and segmental
glomeruloscierosis, interstitial nephritis, and diabetic nephrop-
athy. In contrast to our findings, vascular and tubular basement
membrane clusterin staining was found in rejected allografts
and in cases of interstitial nephritis, but tubular staining of
clusterin was not a major feature of these disorders. French,
Tschopp and Schifferli studied clustenn staining in 180 human
renal biopsies and noted clusterin was usually found in associ-
ation with components of the membrane attack complex, par-
ticularly when the membrane attack complex was associated
with immunoglobulin [17]. Moderate to intense tubular and
vascular staining for clusterin was noted in approximately 24%
of biopsies but the diseases in which tubules stained for
clusterin were not stated. The results of our study provide more
details regarding the tubular expression of clusterin in human
renal disease, and confirm experimental findings demonstrating
predominant tubular induction of clusterin in a variety of injury
states. Since clusterin can bind to the membrane attack com-
plex [21], its localization in human renal diseases could be
attributable to complement deposition, a possibility not tested
for in our study. However, clusterin and complement can be
dissociated in the kidney and other tissues [12, 22] and tubular
epithelial cell deposition of complement is usually not a feature
of many of the disorders studied [23].
Clusterin staining of the epithelial lining of renal cysts con-
firms the observations of Harding et al in the cpk mouse and
extends these findings to human renal cystic diseases [15]. In
the cpk mouse, progressive dilation of collecting duct cysts
occurs leading to renal failure in most mice by three weeks of
age. Clusterin mRNA was present in cystic collecting ducts and
appeared to increase with progressive disease. Clusterin is
developmentally regulated in the kidney, being detected in the
ureteric bud, induced mesenchyme, S-shaped bodies, and col-
lecting ducts of fetal and/or newborn mice [15, 24]. A decrease
in clusterin expression occurs as the kidney matures, being
detectable only in some distal tubular epithelial cells in the adult
kidney. The re-expression of clusterin in the epithelial lining of
collecting duct cysts of the cpk mice prompted Harding et alto
suggest that clusterin is a marker of dedifferentiation of these
epithelial cells [15].
The presence of clusterin in developing tubules, as well as in
various cystic disorders, immature tubules in hypoplastic/dys-
plastic kidneys, injured tubules of rejected allografts, and in
some renal cancer cells indicates some similarities between
these diseased states and undifferentiated states. Common
features defining these diseased states include enhanced prolif-
eration, alterations in the cytoskeleton leading to loss of cell
polarity, and abnormal cell-substratum and cell-cell interac-
tions. For example, loss of polarity, best documented by
redistribution of the sodium-potassium ATPase from the baso-
lateral to apical cell membrane, is observed following renal
tubular injury and in cystic epithelium [25, 26]. Abnormalities in
cell-substratum and cell-cell interactions are found following
renal tubular cell injury, and include loss of focal cell contacts,
internalization of cell adhesion molecules and redistribution of
integrins [27—29]. Perturbations in extracellular matrix compo-
nents and decreased expression of cell adhesion molecules have
been observed in renal cystic diseases and may play a role in the
pathogenesis of the cysts [30—34]. The function of clusterin in
renal disease remains undefined, but likely relates to one or
more of these phenotypic alterations found in immature, cystic
or injured tubules.
We speculate in the setting of renal disease/injury, clusterin
acts as a cohesive factor to maintain proximity of cells (non-
junctional cell contact) as well as cell adhesion to the substra-
tum. Support for this hypothesis derives from the induction of
clusterin in the wide array of renal tubular disorders presented
and the potent ability of clusterin to aggregate cells. Clusterin
induces aggregation of a variety of cells in vitro including
erythrocytes, white blood cells, spermatozoa, mouse testes
TM-4 cells, and primary cultures of rat Sertoli cells [1, 2, 35,
36]. Prolonged incubation of TM-4 cells with clusterin resulted
in the formation of junctional contacts between cells in associ-
ation with increased expression of the cell adhesion molecule
N-CAM, suggesting clusterin may be involved with initial
non-junctional cell aggregation which would then enable more
stable cell-cell interactions to become established [36]. Clus-
tern is not a member of any known class of adhesion molecule
(such as integrins or cadherins), and the biochemical basis by
which it promotes cell interactions is poorly defined. Structural
analysis does reveal several potential heparin binding sites
which could facilitate interaction between clusterin and extra-
cellular matrix [21, 37—39]. Furthermore, the state of cell-
substratum interactions can influence clusterin-induced cell
aggregation. Tung et al demonstrated that cell aggregation
induced by clusterin was greatest when interactions between
cells and substratum were inhibited, suggesting an anchorage
related phenotypic alteration in cells which promotes interac-
tion with clusterin [36].
Maintenance of cell-cell and cell-substratum contact has
obvious advantages to the kidney, as it would prevent loss of
viable cells into the tubular lumen which would not only disrupt
the epithelial barrier leading to backleak of glomerular filtrate,
but the detached cells could also cause tubular obstruction [29,
40, 41]. In addition, maintenance of cell-cell contact would
allow the normal junctional contacts to become re-established
once the injury subsides.
Other proposed roles for clusterin in the setting of tissue
injury include complement defense, apoptosis and membrane
protection. Clusterin can inhibit complement mediated cytoly-
sis by binding to nascent CSb-7 complex preventing insertion of
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Fig. 1. Clusterin expression in human renal disease. A. Normal kidney. No clusterin staining is seen in normal tubular epithelial cells in renal
tissue distant from a renal cell carcinoma. B. Autosomal-dominant polycystic kidney disease. Clusterin positivity in some cysts highlights the focal
nature of its distribution. In a positive cyst, all epithelial cells stain for clusterin, No clusterin staining is present in the interstitium. C.
Autosomal-dominant polycystic kidney disease, Some cysts and tubular casts stain for clusterin. D. Autosomal-dominant polycystic kidney
disease. A high power view of a cyst demonstrating positive staining for clusterin in lining cells and in detached epithelial cells; the latter contribute
to the casts seen in cysts and dilated tubules. E. Multilocular cyst. Clusterin staining of cyst epithelium and detached epithelial cells. F. Renal
dysplasia. A collarette of negatively staining mesenchymal cells encases immature tubules variably staining for clusterin. Adjacent tubules are non
reactive. G. Renal dysplasia. Dilated and normal appearing tubules stain for clusterin. No glomerular staining is seen. H. Renal dysplasia. Clusterin
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staining in the epithelial lining of a cyst in an area of cystic dysplasia. I. Wilms' tumor. No clusterin staining is seen in tumor cells. J. Wilms' tumor.
Positive staining for clusterin is observed in a non-neoplastic tubule entrapped by non-reactive blastematous tumor cells. K. Renal cell carcinoma. Focal,
membrane-based staining for clusterin is observed in some cells. L. Acute renal transplant rejection. Clusterin staining is observed in some tubules and
tubular casts. Tubules containing positively staining casts do not necessarily show immunoreactive lining epithelium (arrow). M. Chronic renal transplant
rejection. Positive clusterin staining is noted in some tubules. No interstitial staining is observed. N. Chronic renal transplant rejection. A positively
staining tubule is seen next to negatively staining tubules and glomerulus. 0. Acute and chronic renal transplant rejection. Intratubular variation in
clusterin staining is observed, with positive and negative epithelial cells present in this tubule. P. Acute and chronic renal transplant rejection. An
epithelial cell cast positive for clusterin is present in the lumen of this tubule; the lining epithelium is moderately positive. Publication in color was made
possible by educational grants from Sandoz Pharmaceuticals, Ortho Biotech, Pfizer Laboratories, and Amgen, Inc.
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the membrane attack complex into cell membranes [21, 42]. The
pathophysiologic relevance of this property of clusterin has not
been determined. The role of clusterin in apoptosis is contro-
versial. Evidence for an association between clusterin and
apoptosis has been provided from studies demonstrating ex-
pression of clusterin at times of apoptosis such as during
prostate atrophy, limb bud regression or treatment of thymo-
cytes with dexamethasone [43—45]. However, many examples
exist where clusterin has been dissociated from apoptosis [4, 7,
46—48]. Clusterin is probably not necessary in initiating apop-
tosis, but may appear as a consequence of apoptosis perhaps to
maintain cell interactions during the apoptotic process. A role
for clusterin as a membrane "policeman" has been proposed by
Jordan-Starck et al based on its ability to interact with hydro-
phobic molecules, its association with membranes, and its
location at interfaces between epithelia and "harsh" environ-
ments [6].
In conclusion, clusterin was expressed in renal tubular epi-
thelium in a number ofhuman renal diseases including autosomal-
dominant and -recessive polycystic kidney disease, multilocular
cysts, renal hypoplasialdysplasia, and acute and chronic renal
transplant rejection. No clusterin was detected in Wilms' tu-
mors, except in one case associated with cystic changes. In
renal cell carcinoma, focal staining for clusterin was present in
some tumors. Based on its potent cohesive properties, we
speculate clusterin functions to maintain cell-cell and/or cell-
substratum contacts which in the setting of renal cystic disease,
tubular injury or immaturity would not only preserve the
integrity of the tubular epithelium but also prevent loss of
potentially viable cells into the tubular lumen.
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